DOCSLIB.ORG

Translational Science

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

CLOSING THE GAP THROUGH TRANSLATIONAL SCIENCE Elias Zerhouni on Blavatnik Awards Support The Science Behind Breaking Down Barriers Early Career Success Contagion www.nyas.org • Autumn 2011 Board of Governors Chair Vice Chair Treasurer NANCY ZIMPHER KENNETH L. DAVIS ROBERT CATELL President [ex offi cio] Secretary [ex offi cio] ELLIS RUBINSTEIN LARRY SMITH Governors LEN BLAVATNIK ELAINE FUCHS THOMAS CAMPBELL JOHN E. SEXTON MARY BRABECK JAY FURMAN JACKSON GEORGE E. THIBAULT NANCY CANTOR ALICE P. GAST JOHN E. KELLY III PAUL WALKER MARTIN CHALFIE BRIAN GREENE MEHMOOD KHAN IRIS WEINSHALL MILTON COFIELD THOMAS L. HARRISON JEFFREY D. SACHS ANTHONY WELTERS ROBIN L. DAVISSON STEVE HOCHBERG KATHE SACKLER FRANK WILCZEK MIKAEL DOLSTEN TONI HOOVER MORTIMER D.A. SACKLER MICHAEL ZIGMAN International Governors Chairman Emeritus Honorary Life Governors SETH F. BERKLEY RAJENDRA K. PACHAURI TORSTEN N. WIESEL KAREN E. BURKE MANUEL CAMACHO SOLIS RUSSELL READ HERBERT J. KAYDEN GERALD CHAN PAUL STOFFELS JOHN F. NIBLACK S. KRIS GOPALAKRISHNAN President’s Council PETER AGRE AARON CIECHANOVER LEON LEDERMAN PHILLIP A. SHARP Nobel Laureate & Univ. Nobel Laureate & Nobel Laureate & Pritzker Nobel Laureate & Director, Prof. and Director, Johns Distinguished Research Prof., Prof. of Science, Illinois McGovern Inst., MIT Center Hopkins Malaria Research Tumor and Vascular Biology Inst. of Tech.; Resident for Cancer Research Inst., Dept. Molecular Research Center, Faculty of Scholar, Illinois Math & ELLIOTT SIGAL On the cover: Bill Oxford / iStockphoto.com Microbiology and Medicine, Technion-Israel Science Academy CSO, Bristol-Myers Squibb Immunology, Bloomberg Inst. of Tech., Haifa, Israel GREGORY LUCIER MICHAEL SOHLMAN School of Public Health GORDON CONWAY Chairman and CEO, Life Former Exec. Director, The RICHARD AXEL Chair in International Technologies Corporation Nobel Foundation Nobel Laureate & Development, Imperial RODERICK MACKINNON PAUL STOFFELS Professor, Columbia Univ.; College London Nobel Laureate & John Company Group Investigator, HHMI PETER DOHERTY D. Rockefeller, Jr. Prof., Chairman, World Wide LEE BABISS Nobel Laureate & The Rockefeller Univ.; Research & Development, Global Head, Pharma Researcher, St. Jude Investigator, HHMI Pharmaceuticals Group, Executive Editor Research, Roche Children’s Research JOEL S. MARCUS Johnson & Johnson Pharmaceuticals Hospital, Memphis, TN; CEO, Alexandria Real MARC TESSIER-LAVIGNE Diana Friedman DAVID BALTIMORE Univ. of Melbourne Estate Equities, Inc. President, The Rockefeller Univ. Nobel Laureate & President MIKAEL DOLSTEN GERALD J. MCDOUGALL MARY ANN TIGHE Emeritus, Caltech President, Worldwide National Partner, Global CEO, New York Tri-State Art Director ETIENNE-EMILE BAULIEU Research and Development; Pharmaceutical & Health Region, CB Richard Ellis Ash Ayman Shairzay Former President, French Sr. VP, Pfi zer Inc Sciences Practice, SHIRLEY TILGHMAN Academy of Sciences MARCELO EBRARD PricewaterhouseCoopers President, Princeton Univ. PAUL BERG CASAUBÓN LLP FRANK WALSH Contributors Nobel Laureate & Prof. Mayor, Mexico City RICHARD MENSCHEL CEO, Ossianix, Inc. Emeritus, Dept. of EDMOND H. FISCHER Sr. Director, Goldman Sachs GERALD WEISSMANN Douglas Braaten, Sonya Dougal, Biochemistry, Stanford Univ. Nobel Laureate & Prof. RONAY MENSCHEL Prof. of Medicine, NYU Brooke Grindlinger, Jamie Kass, LEN BLAVATNIK Emeritus, Dept. of Chairman of the Board, School of Medicine Chairman, Access Industries Biochemistry, Univ. of Phipps Houses; Board of JOHN WHITEHEAD Stephanie Kelly, Marci A. Landsmann, GÜNTER BLOBEL Washington Overseers, Weill Cornell Former Chairman, Lower Noah Rosenberg, Sarah Webb Nobel Laureate & Director, ALAN J. FRIEDMAN Medical College Manhattan Development Laboratory for Cell Biology, Former Director, New York FERID MURAD Corp.; former Co-Chairman The Rockefeller Univ. Hall of Science Nobel Laureate & Director, of Goldman Sachs Editorial Offi ce IRINA BOKOVA JOSEPH GOLDSTEIN IMM Center for Cell GEORGE WHITESIDES Director General, United Nobel Laureate & Chairman, Signaling, The University of Mallinckrodt Prof. of 7 World Trade Center Nations Educational, Molecular Genetics, Univ. Texas at Houston Chemistry, Harvard Univ. Scientifi c and Cultural of Texas Southwestern JOHN F. NIBLACK TORSTEN N. WIESEL 250 Greenwich St, 40th Fl Organization (UNESCO) Medical Center Former President, Pfi zer Nobel Laureate & former New York, NY 10007-2157 SYDNEY BRENNER S. GOPALAKRISHNAN Global Research & Secy. General, Human Nobel Laureate & Exec. Co-Chairman of the Development Frontier Science Program Phone: 212.298.8645 Distinguished Prof., Salk Inst. Board, Infosys Technologies PAUL NURSE Organization; President Fax: 212.298.3655 MICHAEL S. BROWN Limited Nobel Laureate & President, Emeritus, The Rockefeller Nobel Laureate & Prof. of PAUL GREENGARD The Royal Society; former Univ. Email: [email protected] Molecular Genetics, Univ. Nobel Laureate & Prof. President, The Rockefeller FRANK WILCZEK of Texas Southwestern of Molecular & Cellular Univ. Nobel Laureate & Herman Medical Center Neuroscience, The ROBERT C. RICHARDSON Feshbach Professor of Membership Director LINDA BUCK Rockefeller Univ. Nobel Laureate & Sr. Vice Physics, MIT John F. Grifferty Nobel Laureate & GLENDA GREENWALD Provost for Research, ERNST-LUDWIG Investigator for HHMI; President, Aspen Brain Floyd R. Newman Prof. of WINNACKER member of the Fred Forum Foundation Physics, Cornell Univ. Secy. General, Human Membership & Annals Orders Hutchinson Cancer PETER GRUSS RICHARD ROBERTS Frontier Science Program; Research Center President, Max Planck Nobel Laureate & CSO, former Secy. General, Phone: 212.298.8640 KAREN E. BURKE Gesellschaft, Germany New England Biolabs European Research Council; Fax: 212.298.3650 Dermatologist & Research WILLIAM A. HASELTINE EDWARD F. ROVER former President, Deutsche Scientist President, The Haseltine President, The Dana Forschungsgemeinschaft, Email: [email protected] THOMAS R. CECH Foundation for Medical Foundation Germany Nobel Laureate & Sciences and the Arts; F. SHERWOOD ROWLAND ANDREW WITTY Distinguished Prof., Univ. of Chairman, Haseltine Global Nobel Laureate & Prof. of CEO, GlaxoSmithKline Advertising Inquiries Colorado, Boulder Health, LLC Chemistry & Earth Science, ELIAS ZERHOUNI MARTIN CHALFIE ERIC KANDEL Univ. of California, Irvine President, Global Phone: 212.298.8636 Nobel Laureate & William Nobel Laureate & Prof., BENGT SAMUELSSON Research & Development, Email: [email protected] R. Kenan, Jr., Prof. of Physiology & Cell Biology, Nobel Laureate & Prof., Sanofi -Aventis Biological Sciences; Columbia Univ. Medical & Physiological AHMED ZEWAIL Chair, Dept. of Biological KIYOSHI KUROKAWA Chem., Karolinska Inst.; Nobel Laureate & Linus Visit the Academy online Sciences, Columbia Univ. Former Science Advisor to former Chairman, The Pauling Chair of Chemistry CECILIA CHAN the Prime Minister of Japan; Nobel Foundation and Physics, Caltech www.nyas.org Managing Director, Gold Prof., National Graduate IVAN SEIDENBERG GUANGZHAO ZHOU Avenue Ltd. Institute for Policy Studies Chairman of the Board, Verizon Former Chairman, Chinese (GRIPS) ISMAIL SERAGELDIN Association of Science & Director, Bibliotheca Technology Alexandrina, The Library of Alexandria, Egypt AAutumnutumn 22011011 ccontentsontents Columns Blavatnik Awards 2 Letter from the President 1100 Support System by Sarah Webb Introducing a New Editor Th e Blavatink Awards’ recognition of young scientists has proved critical to their continued success. 4 Annals Highlights Recent and upcoming Annals volumes Cover Story 7 Inside the Academy Reports from the directors of 1166 Closing the Gap through Academy programs and news Translational Science about Academy activities by Diana Friedman Moving from scientifi c discoveries to clinical therapeutics requires better 1133 Academy eBriefi ngs collaboration between scientists and clinicians. Sixth International Congress on Shwachman-Diamond Syndrome, From Crumpling Geometries to Member Memoir Graphene Materials, Trash Talk: Options for Converting Our Solid 2233 Defying Defi nition by Marci A. Landsmann Waste to Energy, Innovating on a Elias Zerhouni discusses his desire to break down artifi cial barriers Shoestring: Medical Technologies in science. for the Developing World 2244 Member News Awards, appointments, and Donor Profi le announcements about Academy 2288 A Medical Education Paradigm members for the Future 2266 Calendar by Noah Rosenberg Academy conferences and George Th ibault and the Josiah Macy Jr. Foundation help the Academy meetings in November, December, push progress. January, and February Letter from the President Introducing a New Editor am donating most of this issue’s From the Editor or VEGF, in angiogenesis, which led to President’s Letter to our dynamic groundbreaking clinical trials for cancer- I new editor, Diana Friedman. She has Dear Members, ous tumors. fearlessly taken on a non-trivial challenge: I am thrilled to introduce myself as What Ferrara and other researchers to improve on the tremendous work of the new editor of Th e New York Acad- gave my father was so much more than a our former editor, Adrienne Burke, who, emy of Sciences Magazine. My goal for drug. It was several months of seemingly through sheer magic, made this magazine this publication is two-fold: 1) to meet healthy, high-quality life, in the midst of intellectually rich and stylistically and vi- your needs for timely and scientifi cal- an otherwise relentless, multi-year dis- sually compelling on a shoestring. ly relevant content and
Recommended publications
  • Michael S. Brown, MD

    Michael S. Brown, MD

    DISTINGUISHED PHYSICIANS AND Michael S. Brown, M.D. Sir Richard Roberts, Ph.D. Winner, 1985 Nobel Prize in Physiology or Medicine Winner, 1993 Nobel Prize in Physiology or Medicine MEDICAL SCIENTISTS MENTORING Winner, 1988 Presidential National Medal of Science A globally prominent biochemist and molecular biologist, DELEGATES HAVE INCLUDED... Dr. Brown received the world’s most prestigious medical Dr. Roberts was awarded the Nobel Prize for his prize for his work describing the regulation of the groundbreaking contribution to discovering RNA splicing. cholesterol metabolism. His work laid the foundation for Dr. Roberts is dedicating his future research to GMO crops the class of drugs now called statins taken daily by more than 20 million and food sources, and demonstrating the effect they have on humanity. — GRANDg MASTERS — people worldwide. Ferid Murad, M.D., Ph.D. Mario Capecchi, Ph.D. Boris D. Lushniak, M.D., M.P.H Winner, 1998 Nobel Prize in Physiology or Medicine Academy Science Director The Surgeon General of the United States (acting, 2013-2014) Winner, 2007 Nobel Prize in Physiology or Medicine A world-renowned pioneer in biochemistry, Dr. Murad’s Winner, 2001 National Medal of Science Rear Admiral Lushniak, M.D., M.P.H., was the United award-winning research demonstrated that nitroglycerin Winner, 2001 Lasker Award States’ leading spokesperson on matters of public health, and related drugs help patients with heart conditions by Winner, 2003 Wolf Prize in Medicine overseeing the operations of the U.S. Public Health Service releasing nitric oxide into the body, thus relaxing smooth Mario Capecchi, Ph.D., a biophysicist, is a Distinguished Commissioned Corps, which consists of approximately muscles by elevating intracellular cyclic GMP, leading to vasodilation and Professor of Human Genetics at the University of Utah School of Medicine.
  • Sanofi-Aventis Press Release

    Sanofi-Aventis Press Release

    Sanofi-aventis press release Sanofi-aventis appoints Dr. Elias Zerhouni, President, Global Research & Development Paris, France - December 14, 2010 - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) is pleased to announce the appointment of Dr. Elias Zerhouni as President, Global Research & Development, covering Medicines and Vaccines, effective January 1, 2011. Dr. Zerhouni will report directly to Christopher A. Viehbacher, Chief Executive Officer of sanofi-aventis, and join the Executive Committee and the Management Committee. Marc Cluzel, M.D., Ph.D., will resign as Executive Vice President, R&D but will continue to work closely with Elias as a scientific expert. “I would like to sincerely thank Marc for his long term contribution. His passion for science and commitment thus far has ensured a readiness to lead the implementation of the transformation of R&D over the past few years,” said Christopher A. Viehbacher, Chief Executive Officer of sanofi-aventis. Since his appointment as Scientific Advisor to Christopher Viehbacher in February 2009, Dr. Zerhouni has been instrumental in redesigning the R&D model to foster increased innovation, the first pillar of the Group’s strategy. The effect of this transformation has already delivered results with a reinvigorated R&D that will provide innovative solutions in response to specific, unmet needs of patients. Centered on the patient, the development of scientific networks and openness to the external scientific world has strengthened the creativity and the flexibility of the company and brought a truly entrepreneurial approach to research. “I have had the privilege of working with Elias for a long time. Through his vast experience and visionary approach, he has provided excellent advice and insight and has been central in implementing what is now one of the most promising R&D models in healthcare,” said Christopher A.
  • Knockout Mice and Test-Tube Babies

    Knockout Mice and Test-Tube Babies

    © 2001 Nature Publishing Group http://medicine.nature.com FOREWORD Laskers for 2001: Knockout mice and test-tube babies Compared with mathematics and physics, biology and medi- Oliver Smithies independently devised an ingenious method cine are mainly empirical sciences. As there are no grand uni- of homologous recombination that allows the preplanned fied theories to guide experiments, conceptual advances in and precise mutation of any desired gene among the ~35,000 the biomedical sciences are crucially dependent on techno- contained within the genome of ES cells. Combination of logical innovations. Examples of such innovations that have the Capecchi–Smithies technique of gene targeting with the revolutionized biology include recombinant DNA, DNA se- Evans technique of ES cell biology led to the first knockout quencing, polymerase chain reaction and monoclonal anti- mice in 1989, an exceptional advance that completely bodies. Examples of new technologies that have changed the style of contemporary biomedical science by revolutionized the practice of medicine include the making it possible to study the function of almost any single heart–lung machine and open heart surgery, coronary an- gene. So far, more than 4,000 of the ~35,000 mouse genes giography and coronary bypass have been knocked out, and more surgery, computer-assisted tomog- than 500 mouse models of human raphy and positron-emission to- disease have been created. mography, and immunosuppression Knockout mice are used today by and organ transplantation. thousands of scientists, both in This year’s Lasker Awards cele- academia and in the pharmaceuti- brate the development of two tech- cal/biotechnology industry. nologies that are comparable in The rise of the mouse to such ex- inventiveness and impact to those alted status in biomedical research mentioned above.
  • Lasker Awards Honor Trailblazers in Medical Research and Public Service

    Lasker Awards Honor Trailblazers in Medical Research and Public Service

    EMBARGOED FOR RELEASE UNTIL SEPTEMBER 14, 2009 FROM: The Albert and Mary Lasker Foundation New York, New York CONTACT: Rubenstein Communications, Inc. Charles Zehren 212-843-8590 [email protected] Janet Wootten 212-843-8032 [email protected] 2009 LASKER AWARDS HONOR TRAILBLAZERS IN MEDICAL RESEARCH AND PUBLIC SERVICE: John Gurdon and Shinya Yamanaka, for Breakthrough Research in Nuclear Reprogramming and Stem Cells Brian J. Druker, Nicholas B. Lydon and Charles L. Sawyers, for Lifesaving Discoveries in Treatment of Leukemia Michael R. Bloomberg, for Landmark Policy and Philanthropic Initiatives to Reduce Tobacco Use and Foster Public Health New York, Sept. 13, 2009 - The Albert and Mary Lasker Foundation, which for 64 years has championed the greatest breakthroughs in medical research, today announced the winners of the 2009 Lasker Awards for outstanding accomplishments in basic medical and clinical medical research, and public service. The three awards—recognized as the most prestigious medical research awards in the United States today— honor six visionaries whose insight and courage has led to dramatic advances that will prevent disease and prolong life. John Gurdon of Cambridge University and Shinya Yamanaka of Kyoto University will receive the 2009 Albert Lasker Basic Medical Research Award for breakthrough discoveries into the process that instructs specialized adult cells to form stem cells. Brian J. Druker of Oregon Health & Science University, Nicholas B. Lydon, formerly of Novartis, and Charles L. Sawyers of Memorial Sloan-Kettering Cancer Center will receive the 2009 Lasker~DeBakey Clinical Medical Research Award for groundbreaking work on the treatment of chronic myeloid leukemia. New York City Mayor Michael R.
  • Eulogy for the Clinical Research Center

    Eulogy for the Clinical Research Center

    Eulogy for the clinical research center David G. Nathan, David M. Nathan J Clin Invest. 2016;126(7):2388-2391. https://doi.org/10.1172/JCI88381. Op-Ed The extramural General Clinical Research Center (GCRC) program has been funded for more than 50 years, first by the National Center for Research Resources, NIH, and more recently as part of the Clinical Translational Science Award (CTSA) program through the newly formed National Center for Advancing Translation Sciences (NCATS). The GCRCs represent the federally funded laboratories that employ a highly trained cadre of research nurses, dietitians, and other support staff and in which generations of clinical investigators trained and performed groundbreaking human studies that advanced medical science and improved clinical care. Without the opportunity for adequate discussion, NCATS has now stopped funding these Research Centers. In this “eulogy,” we review the origins and history of the GCRCs, their contributions to the advancement of medicine, and the recent events that have essentially defunded them. We mourn their loss. Find the latest version: https://jci.me/88381/pdf OP-ED The Journal of Clinical Investigation Eulogy for the clinical research center David G. Nathan1 and David M. Nathan2 1Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA. 2Diabetes Center and Clinical Research Center, Massachusetts General Hospital (MGH), Harvard Medical School, Boston, Massachusetts, USA. icans with a desire to learn the biomedical research technology of the early twentieth The extramural General Clinical Research Center (GCRC) program has been century were forced to travel to England, funded for more than 50 years, first by the National Center for Research France, Austria, or Germany.
  • Graduate Students Bring Clinical Know- Throughout Their Dissertation Work

    Graduate Students Bring Clinical Know- Throughout Their Dissertation Work

    Disease Models & Mechanisms 2, 531-533 (2009) Published by The Company of Biologists 2009 COMMUNITY NEWS and a clinical mentor, most commonly one PhD and one MD, Graduate students bring clinical know- throughout their dissertation work. Students first choose a basic how into their lab work through the HHMI science mentor and laboratory, and outline the clinical and Med into Grad program translational potentials of their project. Next, students choose a clinical mentor, who plays an active role in shaping the student’s Ryan J. Hartmaier and Donald R. Shaffer project, meets regularly with the student and thesis committee, and helps to provide access to valuable patient samples. The The launch of the National Institutes of Health (NIH) roadmap in early marriage of a basic and clinical scientist on each student’s 2004 increased the biomedical community’s focus on advisory team sets the stage for fruitful collaborations and a truly translational research by designating significant funding for translational experience. discoveries in basic research that could lead to changes in patient Some of the best learning opportunities take place through care. Scientists who once lived at the bench are increasingly informal coffee shop meetings where a student discusses, with asked to support the clinical significance of their work. To both mentors, the details and direction of a project that will demonstrate their bench-to-bedside applicability, researchers simultaneously address a basic research question and have now feel encouraged to include patient sample analysis to diagnostic or therapeutic potential. The program puts graduate complement a mechanistic study or in vitro mechanistic data to students at the interface between basic science and the clinic, support a population study.
  • Award Winning Research Kyoto University Is Acknowledged As One of the Most Accomplished Research-Oriented Universities in Asia

    Award Winning Research Kyoto University Is Acknowledged As One of the Most Accomplished Research-Oriented Universities in Asia

    Award Winning Research Kyoto University is acknowledged as one of the most accomplished research-oriented universities in Asia. That reputation is 2016 testified by the accolades conferred on our alumni and researchers, most notably nine Nobel Prize laureates who undertook vital research during their time at the university. In addition to those awards, several other Kyoto University faculty members have received major accolades, including two Fields Medalists, one Gauss Prize winner, and five Lasker Award winners. Nobel Prize 1949, Physics 1965, Physics 1981, Chemistry 1987, Physiology and 2001, Chemistry Hideki Yukawa Shinichiro Tomonaga Kenichi Fukui Medicine Ryoji Noyori Susumu Tonegawa 2008, Physics 2008, Physics 2012, Physiology or 2014, Physics Makoto Kobayashi Toshihide Maskawa Medicine Isamu Akasaki Shinya Yamanaka Fields Medal Gauss Prize Kyoto Prize 1970, Mathematics 1990, Mathematics 2006, Mathematics 1995, Basic Sciences 1998, Basic Sciences 2004, 2010, Heisuke Hironaka Shigefumi Mori Kiyoshi Ito Chushiro Hayashi Kiyoshi Ito Advanced Technology Advanced Technology Alan Curtis Kay Shinya Yamanaka Japan Prize Lasker Award 2005, Information and 2005, Cell Biology 1987, Basic Medical 1989, Basic Medical 1998, Basic Medical 2009, Basic Medical 2014, Basic Medical Media Technology Masatoshi Takeichi Research Research Research Research Research Makoto Nagao Susumu Tonegawa Yasutomi Nishizuka Yoshio Masui Shinya Yamanaka Kazutoshi Mori *photos provided by the Japan Prize Foundation ©e Nobel Foundation2012 photo by Alexander Mahmoud Dr. Shinya Yamanaka, director of the Prof. Kayo Inaba, Kyoto University’s Prof. Kazutoshi Mori of Kyoto Center for iPS Cell Research and executive vice-president for gender University’s Graduate School of Science Application (CiRA), receives the 2012 equality, international affairs, and public receiving the 2014 Albert Lasker Award Nobel Prize in Physiology or Medicine.
  • Leading History Elias A. Zerhouni, MD December 19, 2019

    Leading History Elias A. Zerhouni, MD December 19, 2019

    Episode 16: Leading History Elias A. Zerhouni, MD December 19, 2019 American College of Radiology, through its Radiology Leadership Institute (RLI), offers this podcast as one of a series of educational discussions with radiology leaders. The podcasts reflect the perspectives of the individual leaders, not of ACR or RLI. ACR disclaims liability for any acts or omissions that occur based on these discussions. Listeners may download the transcript for their own learning and share with their colleagues in their practices and departments. However, they may not copy and redistribute any portion of the podcast content for any commercial purpose. Episode 16: Leading History Elias A. Zerhouni, MD [00:00:01.282] Geoff: This month, we have an extra special holiday treat for you. As you will soon hear, Elias Zerhouni has had profoundly broad influence both within the field of radiology and well beyond it through the establishment of national policies for the organization and prioritization of health sciences research, advising international heads of state on science and technology strategy, facilitating the global availability of vaccines, and reorganizing one of the world's largest pharmaceutical companies to pivot from small molecule discovery to the development of therapeutic biologics. Elias Zerhouni has fearlessly approached his career as a series of professional disruptions that offer a lesson to us all in taking chances and making bold decisions. [00:00:51.453] No matter where you are in your career, as you listen to Elias's story, I invite you to reflect on your own journey and the decisions that you may be facing.
  • Lasker Interactive Research Nom'18.Indd

    Lasker Interactive Research Nom'18.Indd

    THE 2018 LASKER MEDICAL RESEARCH AWARDS Nomination Packet albert and mary lasker foundation November 1, 2017 Greetings: On behalf of the Albert and Mary Lasker Foundation, I invite you to submit a nomination for the 2018 Lasker Medical Research Awards. Since 1945, the Lasker Awards have recognized the contributions of scientists, physicians, and public citizens who have made major advances in the understanding, diagnosis, treatment, cure, and prevention of disease. The Medical Research Awards will be offered in three categories in 2018: Basic Research, Clinical Research, and Special Achievement. The Lasker Foundation seeks nominations of outstanding scientists; nominations of women and minorities are encouraged. Nominations that have been made in previous years are not automatically reconsidered. Please see the Nomination Requirements section of this booklet for instructions on updating and resubmitting a nomination. The Foundation accepts electronic submissions. For information on submitting an electronic nomination, please visit www.laskerfoundation.org. Lasker Awards often presage future recognition of the Nobel committee, and they have become known popularly as “America’s Nobels.” Eighty-seven Lasker laureates have received the Nobel Prize, including 40 in the last three decades. Additional information on the Awards Program and on Lasker laureates can be found on our website, www.laskerfoundation.org. A distinguished panel of jurors will select the scientists to be honored with Lasker Medical Research Awards. The 2018 Awards will
  • A Challenge a Most- Deserved Honour

    A Challenge a Most- Deserved Honour

    VOL 6 NO 3 AUTUMN 2007 Promoting Cardiovascular Education, Research and Patient Care In This Issue A Challenge 37 A Challenge Over the past 10 years, the A Most- 37 A Most-Deserved Honour Academy has built a base Deserved 38 Executive Committe for international connectiv- ity for promoting cardiovas- 40 Reports from Japan Meeting Honour cular health. This has been 41 Doctor Receives Volvos for Life “HOUSTON -- (October 2, 2007) achieved by establishing Legislation authorizing a Congres- 42 XVII Brazil Forum seven sections and hold- sional Gold Medal for Dr. Michael 43 Lasker Award for Development ing a variety of workshops, E. DeBakey, pioneering heart sur- of Prosthetic Heart Valves symposia and conferences geon and chancellor emeritus of 44 Indian First-in-man Trials all over the world as well as Baylor College of Medicine, is on 47 Turkey Symposium having several publications its way to President George W. and its own website. 48 John Madden’s “Coach’s Corner” Bush for his signature. Currently, the Academy is proposing to promote link- 49 Mendel Symposium II The U.S. Congress today ap- ages among cardiovascular institutes and centres in proved the bill that now will be 50 Dr. William Parmley the area of population health, clinical studies, scientific forwarded to the president. U.S. 50 Dr. Bohdan Lewartowski investigations, prevention and education for improving Senator Kay Bailey Hutchison and 51 Dr. Sergio Dalla-Volta cardiovascular health. This could help facilitate exchang- U.S. Reps. Al Green, Michael Bur- 52 Dr. Garrett Gross es of health professionals and foster collaborations.
  • Interview with Dr. James Wyngaarden (JW) Jennifer Midura (JM), Center for Public Genomics, Institute for Genome Sciences & Policy, Duke University December 8, 2006

    Interview with Dr. James Wyngaarden (JW) Jennifer Midura (JM), Center for Public Genomics, Institute for Genome Sciences & Policy, Duke University December 8, 2006

    Interview with Dr. James Wyngaarden (JW) Jennifer Midura (JM), Center for Public Genomics, Institute for Genome Sciences & Policy, Duke University December 8, 2006 JM: The information I am about to give you and your response will now be recorded. My name is Jennifer Midura and I am a student at Duke University. I am in a course on the history of genomics that includes oral history. One goal is to produce a written transcript of interviews with important figures in genomics. Some of the interviews may be archived or made public through a website. I selected you as the person I would like to interview. The interview should last about 45 minutes. Your participation in this interview is strictly voluntary, and you may withdraw at any time. You do not have to answer every question asked. The information that you provide will be “on the record” and may be attributed to you. This interview is being recorded and I will take written notes during the interview. The interviews that are posted publicly will be archived as a history resource. If you prefer that the interview be used only for the course and not made public, please indicate this. One risk of this study is that you may disclose information that later could be requested for legal proceedings. Or you may say something that embarrasses you or offends someone else when they read it on a public website. The benefit of participating in this study is ensuring that your side of the story is properly portrayed in the history of genomics.
  • Tyears the News Media Have Been Awash in Storie'abljut Increasingly Close Ties Between O College Campuses and Multimillion-Dollar Corpora­ - Tions

    Tyears the News Media Have Been Awash in Storie'abljut Increasingly Close Ties Between O College Campuses and Multimillion-Dollar Corpora­ - Tions

    :,1 C/) In recentyears the news media have been awash in storie'abljut increasingly close ties between o college campuses and multimillion-dollar corpora­ - tions. Our nation's universities, the story goes, reap m enormtus windfalls patenting products of scientific z ****************** ***~1* research that have been primarily funded by taxpay­ ers. Meanwhile, hoping for new streams of revenue SC IENCE SA{E from their innovations, the same universities are o j FOR allowing their research-and their very principles­ m to become compromised by quests for profit. But "Tl is that really the case? Is money really hopelessly o corrupting science? ;0 With Science for Sale, acclaimed journalist Daniel REliI\A~RmS, S. Greenberg reveals that campus capitalism is more ,THE PER I LS, complicated-and less profitable-than media reports C/) would suggest. While universities seek out corporate ",'AND DELUS IIQti;' '" \ funding, news stories rarely note that those industry » ~US ~ dollars are dwarfed by government support and r ·tfti/... ITA!..! s.M other funds. Also, while many universities have set up m technology-transfer offices to pursue profits through patents, many of those offices have been financial **;~:*.** busts. Meanwhile, science is showing signs of provid-: **'. ,. -: . :",,":);::,:!,:::,,:/..<':-:' ', **t*.' '::,:J<;," ****** ***.'*' * ing its own solutions, as highly publicized misdeeds in pursuit of profits have provoked promising counter­ measures within the field. But just because the threat is overhyped, Greenberg argues, doesn't mean that there's no danger. From research that's shifted overseas so corporations can avoid regulations to conflicts of interest in scientific I publishing, the temptations of money will always be I a threat, and they can only be countered through the viqilance of scientists, the press, and the public.